trial · primary record
BET Bromodomain Inhibitor ZEN-3694
Metastatic Colorectal Carcinoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2027-06-30 |
| Primary endpoint | Incidence of adverse events |
| Registry ID | NCT05803382 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:43:49.747Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05803382
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Bet Bromodomain Inhibitor Zen-3694 · compound